Where Global Innovation
and Capital Meet
Sectors ConsumerUniversityEnergyFinancialHealthcareIndustrialITMediaServicesTelecomsTransportThe Art of CVCStartups

Page 274

Tuanche starts engine on $150m IPO

Bertelsmann Asia Investments owns almost 10% of the Chinese automotive marketplace, which has filed to raise up to $150m in a US offering.

Oct 25, 2018

Dome9 reaches Check Point in $175m acquisition

Cloud security software provider Dome9 has been acquired by Check Point for $175m plus stock and options, following $29m in funding from investors including SoftBank.

Oct 25, 2018

Innovent enters public markets with $421m IPO

Legend Holdings, Eli Lilly, Ping An, China Life and Taikang-backed Innovent Biologics priced its shares near the top of the range of to raise $421m.

Oct 24, 2018

Cloudflare looks to deliver 2019 IPO

Cloudflare, which has raised more than $180m from investors including Microsoft, Baidu, Qualcomm Ventures and GV, could command a $3.5bn valuation in the offering.

Oct 24, 2018

Ant Financial backs StoneCo on way to $1.1bn IPO

Payment technology provider StoneCo will raise about $1.1bn if it floats at the top of its range, while Ant Financial is investing $100m through a private placement.

Oct 24, 2018

Chefs Plate reaches HelloFresh's table

Tengelmann-backed Emil Capital will exit meal kit service Chefs Plate in an acquisition by HelloFresh sized in the mid-eight figures.

Oct 24, 2018

ZoneFox enters Fortinet perimeter

Fortinet has acquired Edinburgh Napier spinout ZoneFox for an undisclosed sum and will integrate the company’s machine learning technology into its own cybersecurity offering.

Oct 24, 2018

Tongcheng-eLong journeys towards $1bn IPO

The online travel agency is reportedly seeking $1bn from an initial public offering in Hong Kong that would provide exits to Tencent, Ctrip and Dalian Wanda.

Oct 23, 2018

PhaseBio finds $46m in initial public offering

Orphan disease drug developer PhaseBio Pharmaceuticals, which is commercialising research from Duke University, cut the price of its shares sharply pre-offering.

Oct 23, 2018

PhaseBio finds $46m in initial public offering

Orphan disease drug developer PhaseBio Pharmaceuticals, which counts Johnson & Johnson, Astellas and AstraZeneca as investors, cut the price of its shares sharply pre-offering.

Oct 23, 2018
© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here